<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Antimetabolites: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i507.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i507.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i507.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a> &gt; <a href="41001i500.htm">Cytotoxics</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i506.htm" title="Previous: Doxorubicin">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i1171.htm" title="Next: Pemetrexed">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i507">Antimetabolites</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Antimetabolites</b>
          has no specific interaction information.
        </p><p>Antimetabolites belongs to <b>Cytotoxics</b>
          and will have the following interactions:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b>avoid concomitant use of  cytotoxics with clozapine (increased risk of agranulocytosis)</b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr></tbody></table><p><b>Pemetrexed</b> belongs to
      <b>Antimetabolites</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i340.htm">Pyrimethamine</a></td><td class="cBV"><b>antifolate effect of  pemetrexed increased by pyrimethamine </b></td><td></td></tr></tbody></table><p><b>Raltitrexed</b> belongs to
      <b>Antimetabolites</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i860.htm">Folates</a></td><td class="cBV"><b>manufacturer of  raltitrexed advises avoid concomitant use with folates </b></td><td></td></tr></tbody></table><p><b>Gemcitabine</b> belongs to
      <b>Antimetabolites</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i222.htm">Warfarin</a></td><td> gemcitabine possibly enhances anticoagulant effect of warfarin </td><td></td></tr></tbody></table><p><b>Tioguanine</b> belongs to
      <b>Antimetabolites</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i993.htm">Busulfan</a></td><td>increased risk of hepatotoxicity when  tioguanine given with busulfan </td><td></td></tr></tbody></table><p><b>Cytarabine</b> belongs to
      <b>Antimetabolites</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i480.htm">Digoxin</a></td><td> cytarabine possibly reduces absorption of digoxin <i>tablets</i></td><td></td></tr><tr><td><a href="41001i820.htm">Flucytosine</a></td><td> cytarabine possibly reduces plasma concentration of flucytosine </td><td></td></tr><tr><td><a href="41001i508.htm">Fludarabine</a></td><td>intracellular concentration of  cytarabine increased by fludarabine </td><td></td></tr></tbody></table><p><b>Fludarabine</b> belongs to
      <b>Antimetabolites</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i821.htm">Cytarabine</a></td><td> fludarabine increases intracellular concentration of cytarabine </td><td></td></tr><tr><td><a href="41001i362.htm">Dipyridamole</a></td><td>effects of  fludarabine possibly reduced by dipyridamole </td><td></td></tr><tr><td><a href="41001i513.htm">Pentostatin</a></td><td class="cBV"><b>increased pulmonary toxicity when  fludarabine given with pentostatin (unacceptably high incidence of fatalities)</b></td><td></td></tr></tbody></table><p><b>Fluorouracil</b> belongs to
      <b>Antimetabolites</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






<tr><td><a href="41001i744.htm">Cimetidine</a></td><td>metabolism of  fluorouracil inhibited by cimetidine (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> fluorouracil enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i565.htm">Filgrastim</a></td><td>neutropenia possibly exacerbated when  fluorouracil given with filgrastim </td><td></td></tr><tr><td><a href="41001i170.htm">Metronidazole</a></td><td>metabolism of  fluorouracil inhibited by metronidazole (increased toxicity)</td><td>Interactions do not apply to topical metronidazole preparations </td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td> fluorouracil possibly inhibits metabolism of phenytoin (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i957.htm">Temoporfin</a></td><td class="cBV"><b>increased skin photosensitivity when <i>topical</i>  fluorouracil used with temoporfin </b></td><td></td></tr></tbody></table><p><b>Capecitabine</b> belongs to
      <b>Antimetabolites</b>
          and has the following interaction information:
        </p><div>Capecitabine is a prodrug of fluorouracil</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i22.htm">Allopurinol</a></td><td class="cBV"><b>manufacturer of  capecitabine advises avoid concomitant use with allopurinol </b></td><td></td></tr><tr><td><a href="41001i1048.htm">Erlotinib</a></td><td> capecitabine possibly increases plasma concentration of erlotinib </td><td></td></tr></tbody></table><p><b>Tegafur with uracil</b> belongs to
      <b>Antimetabolites</b>
          but has no specific interaction information.
        </p><div>Tegafur is a prodrug of fluorouracil</div><p><b>Mercaptopurine</b> belongs to
      <b>Antimetabolites</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






<tr><td><a href="41001i22.htm">Allopurinol</a></td><td class="cBV"><b>enhanced effects and increased toxicity of  mercaptopurine when given with allopurinol (reduce dose of mercaptopurine to one quarter of usual dose)</b></td><td></td></tr><tr><td><a href="41001i928.htm">Aminosalicylates</a></td><td>possible increased risk of leucopenia when  mercaptopurine given with aminosalicylates </td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> mercaptopurine possibly reduces anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i1178.htm">Febuxostat</a></td><td class="cBV"><b>avoidance of  mercaptopurine advised by manufacturer of febuxostat </b></td><td></td></tr><tr><td><a href="41001i208.htm">Sulfamethoxazole</a></td><td class="cBV"><b>increased risk of haematological toxicity when  mercaptopurine given with sulfamethoxazole (as co-trimoxazole)</b></td><td></td></tr><tr><td><a href="41001i217.htm">Trimethoprim</a></td><td class="cBV"><b>increased risk of haematological toxicity when  mercaptopurine given with trimethoprim (also with co-trimoxazole)</b></td><td></td></tr></tbody></table><p><b>Methotrexate</b> belongs to
      <b>Antimetabolites</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




























<tr><td><a href="41001i551.htm">Acetazolamide</a></td><td>excretion of  methotrexate increased by alkaline urine due to acetazolamide </td><td></td></tr><tr><td><a href="41001i683.htm">Acitretin</a></td><td class="cBV"><b>plasma concentration of  methotrexate increased by acitretin (also increased risk of hepatotoxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i361.htm">Aspirin</a></td><td class="cBV"><b>excretion of  methotrexate reduced by aspirin (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b>risk of toxicity when  methotrexate given with ciclosporin </b></td><td></td></tr><tr><td><a href="41001i195.htm">Ciprofloxacin</a></td><td>excretion of  methotrexate possibly reduced by ciprofloxacin (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i877.htm">Cisplatin</a></td><td class="cBV"><b>increased pulmonary toxicity when  methotrexate given with cisplatin </b></td><td></td></tr><tr><td><a href="41001i64.htm">Diclofenac</a></td><td class="cBV"><b>excretion of  methotrexate reduced by diclofenac (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td> methotrexate possibly reduces absorption of digoxin <i>tablets</i></td><td></td></tr><tr><td><a href="41001i212.htm">Doxycycline</a></td><td>increased risk of  methotrexate toxicity when given with doxycycline </td><td></td></tr><tr><td><a href="41001i783.htm">Ibuprofen</a></td><td class="cBV"><b>excretion of  methotrexate reduced by ibuprofen (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr><tr><td><a href="41001i70.htm">Indometacin</a></td><td class="cBV"><b>excretion of  methotrexate reduced by indometacin (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr><tr><td><a href="41001i71.htm">Ketoprofen</a></td><td class="cBV"><b>excretion of  methotrexate reduced by ketoprofen (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr><tr><td><a href="41001i891.htm">Leflunomide</a></td><td class="cBV"><b>risk of toxicity when  methotrexate given with leflunomide </b></td><td>Increased risk of toxicity with other haematotoxic and hepatotoxic drugs</td></tr><tr><td><a href="41001i74.htm">Meloxicam</a></td><td class="cBV"><b>excretion of  methotrexate reduced by meloxicam (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr><tr><td><a href="41001i76.htm">Naproxen</a></td><td class="cBV"><b>excretion of  methotrexate reduced by naproxen (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr><tr><td><a href="41001i133.htm">Neomycin</a></td><td>absorption of  methotrexate possibly reduced by neomycin </td><td></td></tr><tr><td><a href="41001i52.htm">Nitrous Oxide</a></td><td class="cBV"><b>antifolate effect of  methotrexate increased by nitrous oxide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i60.htm">NSAIDs</a></td><td class="cBV"><b>excretion of  methotrexate probably reduced by NSAIDs (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td><i>See also </i>Aspirin. Interactions do not generally apply to topical NSAIDs
</td></tr><tr><td><a href="41001i752.htm">Omeprazole</a></td><td>excretion of  methotrexate possibly reduced by omeprazole (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i174.htm">Penicillins</a></td><td>excretion of  methotrexate reduced by penicillins (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>antifolate effect of  methotrexate increased by phenytoin </td><td></td></tr><tr><td><a href="41001i663.htm">Probenecid</a></td><td class="cBV"><b>excretion of  methotrexate reduced by probenecid (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i340.htm">Pyrimethamine</a></td><td class="cBV"><b>antifolate effect of  methotrexate increased by pyrimethamine </b></td><td></td></tr><tr><td><a href="41001i208.htm">Sulfamethoxazole</a></td><td class="cBV"><b>increased risk of haematological toxicity when  methotrexate given with sulfamethoxazole (as co-trimoxazole)</b></td><td></td></tr><tr><td><a href="41001i203.htm">Sulfonamides</a></td><td>increased risk of  methotrexate toxicity when given with sulfonamides </td><td></td></tr><tr><td><a href="41001i216.htm">Tetracycline</a></td><td>increased risk of  methotrexate toxicity when given with tetracycline </td><td></td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td> methotrexate possibly increases plasma concentration of theophylline </td><td></td></tr><tr><td><a href="41001i217.htm">Trimethoprim</a></td><td class="cBV"><b>increased risk of haematological toxicity when  methotrexate given with trimethoprim (also with co-trimoxazole)</b></td><td></td></tr></tbody></table></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="41001i1171.htm" title="Pemetrexed">Pemetrexed</a></li><li><a href="41001i1166.htm" title="Raltitrexed">Raltitrexed</a></li><li><a href="41001i1148.htm" title="Gemcitabine">Gemcitabine</a></li><li><a href="41001i1041.htm" title="Tioguanine">Tioguanine</a></li><li><a href="41001i821.htm" title="Cytarabine">Cytarabine</a></li><li><a href="41001i508.htm" title="Fludarabine">Fludarabine</a></li><li id="_41001i509"><a href="41001i509.htm" title="Fluorouracil">Fluorouracil</a></li><li><a href="41001i510.htm" title="Mercaptopurine">Mercaptopurine</a></li><li><a href="41001i511.htm" title="Methotrexate">Methotrexate</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i506.htm">Previous: Doxorubicin</a> | <a class="top" href="41001i507.htm#">Top</a> | <a accesskey="]" href="41001i1171.htm">Next: Pemetrexed</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>